Latest News and Press Releases

Company announcement – No. 11 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 5, 2024 – Zealand Pharma A/S (“Zealand”)...

Press release – No. 3 / 2023 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen:...

Company Announcement – No. 10 / 2024 Zealand Pharma convenes its Annual General Meeting 2024 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the...

Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...

Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to...

Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand...

Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....

Company announcement – No. 5 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 19 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL)...

Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...